Cancer drug enters clinical trials

June 2011
Edge (East Carolina University);Summer2011, p4
The article reports on the start of clinical testing on an antibody for treating cancer created by the late Doctor Anne Kellogg of the Brody School of Medicine at East Carolina University through a collaboration between biotechnology firm ImmunoGen and pharmaceutical company Sanofi-aventis.


Related Articles

  • FURTHER READING.  // PharmaWatch: Cancer;Feb2008, Vol. 7 Issue 2, p22 

    A list of articles related to cancer therapies is presented.

  • Mission to sell.  // New Scientist;5/25/91, Vol. 130 Issue 1770, p18 

    Reveals that a delegation of British biotechnology companies is on a trip to Japan this week to promote their research and development services and to look for partners for joint ventures. Possible collaboration for joint research programs into anti-cancer drugs; More.

  • Cool new biz freezes cancer cells. Santiago, Raquel // Crain's Cleveland Business;02/05/2001, Vol. 22 Issue 6, p1 

    Focuses on the efforts of Orange, Ohio-based biotechnology firm Cryoma Labs in banking on biotechnology advances that will enable the development of treatment for various types of cancer. Company's offering of the opportunity for cancer patients to store afflicted tissues for future use in the...

  • Manufacturing to Meet Patient Demand. Mechsler, Jill; Wechsler, Jill // BioPharm International;Aug2001, Vol. 14 Issue 8, p36 

    Discusses issues concerning the United States biotechnology industry as of August 2001. Information on the BIO 2001 meeting in San Diego, California; Production challenges for biotechnology manufacturers; Therapy developed by ImClone Systems that demonstrated effectiveness in treating...

  • Biotech firm, investors await results of trials. Messina, Judith // Crain's New York Business;09/27/99, Vol. 15 Issue 39, p4 

    Reports on New York City-based biotech firm ImClone Systems Inc. Increase in share prices as it turned in encouraging data in trials of its C225 drug in treating certain head and neck cancers. Targeting of a potential North American market by 2004.

  • COMPANY SPOTLIGHT - Amgen.  // PharmaWatch: Monthly Review;Oct2009, Vol. 8 Issue 10, p32 

    The article offers information on the biotechnology company Amgen Inc. It states that the company reported positive topline results such as the Phase III evaluation of Vectibix combined with Folfiri for the treatment of metastatic colorectal cancer (mCRC). It notes that the company focuses on...

  • Molecularly Targeted Therapeutics for Breast Cancer. Hussain, Syed A.; Palmer, Daniel H.; Spooner, David; Rea, Daniel W. // BioDrugs;2007, Vol. 21 Issue 4, p215 

    Thomas Beatson’s celebrated description in 1896 of bilateral oophorectomy as effective therapy for premenopausal breast cancer could be considered as the first demonstration of response of any cancer to a ‘targeted therapy.’ At that time, however,...

  • Biotech: Healthy investments or afflicted by a bubble? Amaral, Rodrigo // Fundweb;9/9/2013, p11 

    The article reports that the biotechnology firms which deliver a revolutionary treatment for serious diseases can be riskly investments. The field of cancer treatment is the most interesting one for buyers, which are able to command especially high prices in the market. Small companies can also...

  • Compounds with Promise Offer Hope of New Cancer Therapies. Kingman, Sharon // BioWorld International;5/14/2008, Vol. 13 Issue 20, p1 

    The article discusses research on a class of compounds called tenovins that has the potential to lead to novel drugs to treat cancer. It references a study by Sonia Lin and colleagues published in the May 5, 2008 issue of "Cancer Cell." According to Lin, tenovins inhibits enzymes called...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics